Primary Sclerosing Cholangitis clinical trials at University of California Health

6 in progress, 5 open to eligible people

Showing trials for

  • A Study of Experimental PLN-74809 in Cholangitis and Suspected Liver Fibrosis

    open to eligible people ages 18-75

    A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis

    at UC Davis UCSF

  • A Study of Volixibat to Treat Itching Caused by Primary Sclerosing Cholangitis

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 16 years and up

    The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

    at UC Davis

  • CM-101 in PSC Patients -The SPRING Study

    open to eligible people ages 18-75

    This study is designed to assess the safety, tolerability and activity of the anti-human CCL24 monoclonal antibody CM-101 in adult subjects with Primary Sclerosing Cholangitis (PSC). At least 93 subjects at approximately 75 sites will be randomized to receive either CM-101 at doses of 5 mg/kg, 10 mg/kg, or 20 mg/kg or matching placebo.

    at UC Davis

  • Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

    open to eligible people ages 15-80

    This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC.

    at UC Davis

  • Liver Cirrhosis Network Cohort Study

    open to eligible people ages 18 years and up

    Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.

    at UCSD UCSF

  • Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

    Sorry, not yet accepting patients

    This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

    at UCSD UCSF

Our lead scientists for Primary Sclerosing Cholangitis research studies include .

Last updated: